Evidence map›Paper›PMID 36334040›Full record

ArticleClinical and experimental immunology2022

Autoinflammatory manifestations in adult patients.

Stefano Rodolfi, Irene Nasone, Marco Folci, Carlo Selmi, Enrico Brunetta

Open access · bronzeAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Stefano RodolfiRheumatology and Clinical Immunology IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Irene NasoneDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Marco FolciNephrology and Internal Medicine, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Carlo SelmiRheumatology and Clinical Immunology IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.ORCID 0000-0002-0323-0376
Enrico BrunettaNephrology and Internal Medicine, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Humanitas University · ITIRCCS Humanitas Research Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoinflammatory diseases represent a family of immune-mediated conditions characterized by the unchecked activation of innate immunity. These conditions share common clinical features such as recurrent fever, inflammatory arthritis, and elevation of acute phase reactants, in the absence of an identified infectious etiology, generally without detectable serum autoantibodies, with variable response to glucocorticoids and in some cases colchicine, which represented the mainstay of treatment until cytokine blockade therapies became available. The first autoinflammatory diseases to be described were monogenic disorders caused by missense mutations in inflammasome components and were recognized predominantly during childhood or early adulthood. However, the progress of genetic analyses and a more detailed immunological phenotyping capacity led to the discovery a wide spectrum of diseases, often becoming manifest or being diagnosed in the adult population. The beneficial role of targeting hyperinflammation via interleukin 1 in complex non-immune-mediated diseases is a field of growing clinical interest. We provide an overview of the autoinflammatory diseases of interest to physicians treating adult patients and to analyze the contribution of hyperinflammation in non-immune-mediated diseases; the result is intended to provide a roadmap to orient scientists and clinicians in this broad area.

Indexed as

ArthritisHereditary Autoinflammatory DiseasesAdultHumansImmunity, InnateInflammasomesInterleukin-1InflammasomesInterleukin-1anakinracanakinumabCOVID-19inflammasomeinterleukin-1myocarditis

Identifiers

PMID36334040
PMCPMC9985169
OpenAlexW4308239191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.